Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug

Blockhead09-20

Novo Nordisk (NVO) stock tumbled Friday — pulling Corbus Pharmaceuticals (CRBP) into a steep dive — after its new approach to weight loss caused neuropsychiatric side effects. ↑ X How Novo ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468782676?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt-150x150.jpg","is_english":true,"pubTime":"2024-09-20 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468782676","market":"sg","top_or_hot":-1,"title":"Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug","media":"Blockhead","content":"<div>\n<p>Novo Nordisk (NVO) stock tumbled Friday — pulling Corbus Pharmaceuticals (CRBP) into a steep dive — after its new approach to weight loss caused neuropsychiatric side effects.\n\n\n\n↑\nX\n\n\n\n\nHow Novo ...</p>\n\n<a href=\"https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-neuropsychiatric-side-effects/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-20 23:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-neuropsychiatric-side-effects/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk (NVO) stock tumbled Friday — pulling Corbus Pharmaceuticals (CRBP) into a steep dive — after its new approach to weight loss caused neuropsychiatric side effects.\n\n\n\n↑\nX\n\n\n\n\nHow Novo ...</p>\n\n<a href=\"https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-neuropsychiatric-side-effects/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKVL7J92.USD","symbol_name":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","start_time":0,"source_url":"https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-neuropsychiatric-side-effects/","article_id":"2468782676","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468782676","pubTimestamp":1726846405,"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SNY":"赛诺菲安万特","BK4585":"ETF&股票定投概念","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4139":"生物科技","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4007":"制药","GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0238689110.USD":"贝莱德环球动力股票基金","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU0079474960.USD":"联博美国增长基金A","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","CRBP":"Corbus Pharmaceuticals Holdings, Inc.","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4516":"特朗普概念","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","BK4588":"碎股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LLY":"礼来","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4581":"高盛持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","NVO.AU":"NOVO RESOURCES CORP-CDI","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","TERN":"Terns Pharmaceuticals, Inc.","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","VKTX":"Viking Therapeutics, Inc.","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","NVO":"诺和诺德","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS"},"translate_title":"Novo因减肥药的精神副作用而潜水，Corbus崩溃","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1,"GPCR":1,"CRBP":1,"NVO":1,"NVO.AU":1,"SNY":1,"TERN":1,"LLY":0.6},"content_text":"Novo Nordisk (NVO) stock tumbled Friday — pulling Corbus Pharmaceuticals (CRBP) into a steep dive — after its new approach to weight loss caused neuropsychiatric side effects.\n\n\n\n↑\nX\n\n\n\n\nHow Novo Nordisk, Wegovy And Ozempic Are Changing The Weight-Loss Game For Patients And Investors\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow Novo Nordisk, Wegovy And Ozempic Are Changing The Weight-Loss Game For Patients And Investors\n\n\n\n\nThe Denmark-based drugmaker tested a new pill it acquired with Inversago Pharmaceuticals last year in patients with obesity and metabolic syndrome. The pill works differently from Novo's other weight-loss drug, semaglutide, which mimics the GLP-1 hormone. This drug, dubbed monlunabant, blocks a cannabinoid receptor. This receptor helps regulate weight and energy balance.\nAt the lowest dose, patients lost 7.1 kilograms (or roughly 16 pounds) over 16 weeks, compared with a 0.7-kilogram (or 1.5-pound) loss for the placebo group. Patients started with a baseline weight of 110.1 kilograms (242 pounds). Higher doses didn't lead to greater weight loss, Novo Nordisk said in a news release.\nBut the same gastrointestinal side effects that plague the GLP-1 drug class also showed up in patients who received the cannabinoid receptor-targeting drug. Further, monlunabant recipients experienced mild to moderate neuropsychiatric side effects, including anxiety, irritability and sleep disturbances.\nMartin Holst Lange, Novo Nordisk's head of development, said the company still needs to \"determine the optimal dosing to balance safety and (effectiveness).\" Novo Nordisk is now planning to run a second midstage study in 2025.\nIn morning trades, Novo Nordisk stock tumbled more than 5% to 126.83. Shares of Corbus, which is working on a similar weight-loss drug, crashed 60.2% to 20.59.\nMeanwhile, shares of companies working on GLP-1-based drugs jumped. Eli Lilly (LLY) stock rose 2% to 932.99. Shares of Viking Therapeutics (VKTX), Structure Therapeutics (GPCR) and Terns Pharmaceuticals (TERN) advanced a respective 5.4%, 8% and 3.9%.\nWeight Loss 'Underwhelming'\nThe neuropsychiatric side effects aren't entirely unexpected. Leerink Partners analyst David Risinger notes Sanofi (SNY) had a cannabinoid receptor 1-targeting drug approved in Europe for weight loss. But it penetrated the central nervous system and led to neuropsychiatric side effects. It was later withdrawn from the market.\n\"Interestingly, Novo announced plans to initiate a Phase 2b obesity trial in 2025,\" he said in a report. \"We think that the decision is driven by the company's interest in diversifying its obesity portfolio.\"\nRisinger doesn't have a rating on Novo Nordisk stock.\nHe also says the 6.3% difference in weight loss between monlunabant patients and placebo recipients is \"underwhelming.\" In another 16-week study, Eli Lilly's pill, orforglipron, led to 8% placebo-adjusted weight loss. But Novo executives projected 15% weight loss with monlunabant.\nCorbus' Drug Could Be Safer\nBut RBC Capital Markets analyst Brian Abrahams says the drug could still find a market. It's hard to determine because Novo Nordisk didn't outline the event rates or severity.\n\"There was no mention of suicidal ideation or depression, with most events likely irritability and anxiety, which we believe may still be acceptable,\" he said in a report. \"Recall too, that monlunabant had demonstrated about 14% placebo-adjusted increases in psychiatric adverse events in Phase 1 (testing).\"\nHe believes Corbus' drug could have an advantage when it comes to safety. Roughly one-tenth the amount of drug ends up in the brain, he said. This could mitigate the neuropsychiatric side effects and still lead to weight loss.\nAbrahams didn't list a rating for Novo Nordisk stock, but rates Corbus stock an outperform.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nGeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics\n2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?\nIBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks\nJoin IBD Live For Stock Ideas Each Morning Before The Open\nLearn How To Time The Market With IBD's ETF Market Strategy","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468782676"}